SCHEMBL11289154

SCHEMBL11289154

Cc1ccccc1NC=S

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
HTT P42858 3/20 0.48
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
ALDH1A1 P00352 5/20 0.44
GAA P10253 4/20 0.44
POLB P06746 2/20 0.44
HPGD P15428 4/20 0.43
DHODH Q02127 1/20 0.43
KDM4E B2RXH2 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
RECQL P46063 1/20 0.41
TSHR P16473 1/20 0.41
ACHE P22303 1/20 0.41
LMNA P02545 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
EPHX1 P07099 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8764228 0.82 ALDH1A1 (0.35) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL13257963 0.80 NPC1 (0.54) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL20960554 0.78 ALDH1A1 (0.51) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL3127028 0.78 MAPT (0.50) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL1485944 0.76 MAPT (0.48) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL9800976 0.76 NPC1 (0.50) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL10893987 0.76 MAPT (0.48) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL18799832 0.76 NPC1 (0.50) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL20197190 0.76 NPC1 (0.50) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL225741 0.76 NPC1 (0.50) MAPTHTTNPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150368271-A1 CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR HUTCHISON MEDIPHARMA LIMITED (CN) 2015-12-24 US disclosed
EP-1833816-B1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS NOVARTIS AG (CH) 2009-11-11 EP disclosed
US-4352928-A ANTIINFLAMMATORY, HYPOGLYCEMIC, ANTICOAGULANT, ANOREXIGENIC, SEROTONIN EFFEC MITSUBISHI YUKA PHARMACEUTICAL CO., LTD. (JP) 1982-10-05 US disclosed
EP-0022481-A1 5,6-Alkylenepyrimidine derivatives, processes for preparing the same and pharmaceutical compositions Mitsubishi Yuka Pharmaceutical Co., Ltd. (JP) 1981-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368271-A1 CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR KCNJ11, NISCH, CYP4Z1 MAPT 3267/4885HTT 2558/4885NPC1 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.